Dow Jones
33.891,02 -34,99 (-0,10%) Nasdaq
11.887,45 -119,50 (-1,00%) Nikkei 225
27.693,65 +184,19 (+0,67%) EUR/USD
1,0730 -0,0067 (-0,62%) BTC-EUR
21.234,20 -335,84 (-1,56%) CMC Crypto 200
527,84 +2,70 (+0,51%)
Aptose Biosciences Inc. (0UI8.L)
| Chiusura precedente | 7,4200 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 1,56 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,8750 |
| Prossima data utili | 20 mar 2023 - 24 mar 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
• AML Patients Receive Tuspetinib Monotherapy to Kick Off APTIVATE Phase 1/2 Trial• New Response Emerges with 40 mg Tuspetinib in FLT3 Wildtype AML Patient• Aptose Elucidates Rationale for Tuspetinib’s Superior Safety Profile SAN DIEGO and TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase 1/2 clinical trial of tuspetinib (formerly HM43239), an oral, mutation agnost
- GlobeNewswire
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate at the upcoming Biotech Showcase™ 2023 Conference on Tuesday, January 10th, 2023, at 10:00 a.m. PST in San Francisco, CA. Conference Presentation D
- GlobeNewswire
Aptose Biosciences Establishes New At-The-Market Facility
SAN DIEGO and TORONTO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced it has entered into an equity distribution agreement (the “Equity Distribution Agreement”) with JonesTrading Institutional Services LLC, as agent (the “Agent”). Under the terms of the Equity Distribution Agreement,
